MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Strona główna・Stock List・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Closed

SectorHealthcare

0.27 3.85

Buy Sell

Overview

Share price change

24h

Current

Min

0.27

Max

0.28

Key metrics
By Trading Economics
Income	-2.5M -37M
Sales	14M 14M
EPS	-0.111
Profit margin	-262.996
Employees	142
EBITDA	10M -23M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+2042.86% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-18M 106M
Previous open	-3.58
Previous close	0.27

News Sentiment

By Acuity

31%

69%

91 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.5207 / 0.7223 Support & Resistance

Sangamo Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 kwi 2026, 23:26 UTC

Hot Stocks

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 kwi 2026, 20:41 UTC

Major Market Movers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 kwi 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 kwi 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 kwi 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 kwi 2026, 22:08 UTC

Earnings

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

16 kwi 2026, 20:49 UTC

Earnings

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 kwi 2026, 20:43 UTC

Earnings

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Netflix Says Engagement Quality Hits New High -- Market Talk

16 kwi 2026, 20:30 UTC

Hot Stocks

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 kwi 2026, 20:25 UTC

Earnings

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:23 UTC

Earnings

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 kwi 2026, 20:19 UTC

Earnings

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Comparison

Price change

Sangamo Therapeutics Inc Forecast

Price Target

By TipRanks

2042.86% upside

12 Months Forecast

Average 6 USD 2042.86%

High 10 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forSangamo Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Sangamo Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.5207 / 0.7223Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

91 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.